TandemAI Closes $22M Series A Extension Round to Accelerate AI-Driven Drug Discovery

NEW YORK & BOSTON--(BUSINESS WIRE)--TandemAI announced it has secured a $22 million Series A extension to further develop its drug discovery platform, which combines advanced AI, physics-based computational methods, and wet lab capabilities. The round included both new and existing investors. Since its founding in October 2021, the company has raised over $80M.

With a team of more than 300 professionals, TandemAI’s AI-powered, fully integrated drug discovery engine has delivered over ten high-value, highly differentiated candidates that are now in—or soon to enter—clinical development. The company has also partnered with four of the world’s top ten multinational pharmaceutical companies, building a network of more than 150 global partners and clients.

“TandemAI has successfully executed on its approach to build and commercialize a powerful drug discovery platform by integrating AI and physics-based computational technologies with wet lab techniques,” said Peter Zhao, Managing Director at V-Capital. “With this funding, the company and its outstanding team are well positioned to grow its existing small molecule business and, with the recent merger with Perpetual Medicines, capitalize on the significant emerging opportunities in peptide and antibody-peptide conjugate discovery.”

KHK Fund stated, “AI and advanced physics-based methods are now essential for drug discovery. TandemAI’s platform has notably enhanced R&D efficiency and success rates in small molecule and peptide drug discovery, driving rapid growth even during the pharmaceutical market downturn. We are pleased to support the company’s continued growth.”

“The financing is a strong vote of confidence in our progress to date and in our strategy,” said Jeff He, co-founder and CEO of TandemAI. “This funding will support AI and computational physics-based model development for multiple modalities, as well as wet lab capacity expansion to accommodate our rapidly growing client base.” Mr. He noted that the strategic merger with Perpetual Medicines also brought on board seasoned drug developers Kerry Blanchard, MD, PhD and Ved Srivastava, PhD, further enhancing TandemAI’s end-to-end drug discovery and development expertise.

About TandemAI

TandemAI is transforming drug discovery by integrating generative AI, physics-based modeling (molecular dynamics and quantum mechanics), an AI-powered, next generation SaaS platform, TandemViz™, and large-scale chemistry and biology labs. This computation-first approach covers the entire drug development process, from target prediction to clinical candidate determination, significantly boosting efficiency and success rates for global pharmaceutical organizations.

In just four years, TandemAI has established a global R&D, serving over 150 biopharmaceutical companies and accelerating more than 50 innovative drug pipelines. The company has achieved 10x revenue growth, earning accolades like "China Innovative Digital Healthcare TOP100," "Forbes Asia 100 to Watch," and inclusion in the "Nature Index Global AI Drug Discovery Innovation Landscape".

TandemViz™, the world's first one-stop AI-enabled drug discovery platform, integrates cutting edge computational modules, an optimized high-performance computing infrastructure, and data management, enhancing productivity and accessibility. This platform addresses key R&D challenges, driving rapid dry-wet lab integration and gaining widespread industry recognition. For additional information, please visit https://tandemai.com/